keyword
https://read.qxmd.com/read/38511310/atrial-septal-defect-pulmonary-arterial-hypertension-and-diastolic-left-heart-failure-when-3-players-come-into-the-game
#21
JOURNAL ARTICLE
Tobias Rutz, John-David Aubert, Maurice Beghetti, Eric Eeckhout, Olivier Muller, Judith Bouchardy, Patrick Yerly
No abstract text is available yet for this article.
March 21, 2024: Circulation. Heart Failure
https://read.qxmd.com/read/38511072/prescribing-patterns-of-sglt-2-inhibitors-for-patients-with-heart-failure-a-two-center-analysis
#22
JOURNAL ARTICLE
Teja Chakrala, Roshni O Prakash, Justin Kim, Hanzhi Gao, Umar Ghaffar, Jaymin Patel, Alex Parker, Bhagwan Dass
BACKGROUND: Sodium glucose co-transporter 2 inhibitors (SGLT2i) have been proven to reduce the combined risk of cardiovascular death and hospitalizations in patients with heart failure (HF), irrespective of the presence or absence of diabetes. Despite class 1 and class 2A recommendations for their usage in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) respectively by the American College of Cardiology, their prescription rate has remained low...
April 2023: American heart journal plus: cardiology research and practice
https://read.qxmd.com/read/38510717/caloric-restriction-rejuvenates-skeletal-muscle-growth-in-heart%C3%A2-failure-with-preserved-ejection-fraction
#23
JOURNAL ARTICLE
Ever Espino-Gonzalez, Peter G Tickle, Raffaele Altara, Harrison Gallagher, Chew W Cheng, Viktor Engman, Nathanael Wood, Gustavo Jose Justo da Silva, Mattia Scalabrin, Xinyue Yu, Ziyi Zhong, Michael A Colman, Nadira Y Yuldasheva, George W Booz, Volker Adams, Marcelo G Pereira, Alessandro Cataliotti, Lee D Roberts, Stuart Egginton, T Scott Bowen
Heart failure with preserved ejection fraction (HFpEF) is a major clinical problem, with limited treatments. HFpEF is characterized by a distinct, but poorly understood, skeletal muscle pathology, which could offer an alternative therapeutic target. In a rat model, we identified impaired myonuclear accretion as a mechanism for low myofiber growth in HFpEF following resistance exercise. Acute caloric restriction rescued skeletal muscle pathology in HFpEF, whereas cardiac therapies had no effect. Mechanisms regulating myonuclear accretion were dysregulated in patients with HFpEF...
February 2024: JACC. Basic to Translational Science
https://read.qxmd.com/read/38510554/a-review-of-the-impact-pathophysiology-and-management-of-atrial-fibrillation-in-patients-with-heart-failure-with-preserved-ejection-fraction
#24
REVIEW
Cicely Dye, Mark Dela Cruz, Timothy Larsen, Gatha Nair, Karolina Marinescu, Tisha Suboc, Erica Engelstein, Jennifer Marsidi, Priya Patel, Parikshit Sharma, Annabelle Santos Volgman
Patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have increased mortality and increased risk of stroke. Due to the heterogeneous nature of both disease processes, it is difficult to ascertain whether the diagnosis and progression of AF is the cause of deterioration or if it is a symptom of worsening heart failure. This presents physicians with a clinical conundrum of whether optimizing their heart failure will decrease the overall AF burden or if restoration of sinus rhythm is necessary to optimize patients with HFpEF...
September 2023: American heart journal plus: cardiology research and practice
https://read.qxmd.com/read/38510032/association-of-hypertension-burden-with-stroke-risk-in-patients-with-heart-failure-with-preserved-ejection-fraction
#25
JOURNAL ARTICLE
Siyu Guo, Xiao Liu, Zhenbang Gu, Junyi Sun, Yalin Cao, Wengen Zhu
INTRODUCTION: Whether the hypertension burden is associated with stroke incidence is inconclusive. In this study, we aimed to investigate the relationship between hypertension burden and stroke risk in patients with heart failure with preserved ejection fraction (HFpEF). METHODS: HFpEF patients from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial were divided into three groups (low, medium, and high risk) according to their hypertension burden values...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38509766/frailty-in-clinical-drug-trials-frailty-assessments-subgroup-analyses-and-outcomes
#26
REVIEW
Tu N Nguyen, Fahed Ahmad, Richard I Lindley
With population ageing, drug trials are increasingly turning their attention to including older, frailer people. This review aimed to provide an overview of how frailty was assessed in published studies related to clinical pharmacological trials, and on the interaction of frailty on the efficacy of the treatments. We searched MEDLINE, EMBASE and Cochrane for clinical drug trials in older people. A total of 4031 abstracts were screened and 17 relevant studies were included in this review. We summarized the findings of these 17 trials into five main clinical areas: cardiovascular (eight studies), cognition (one study), vaccination (two studies), cancer (four studies) and other (two studies)...
March 21, 2024: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/38509729/hbi-8000-improves-heart-failure-with-preserved-ejection-fraction-via-the-tgf-%C3%AE-1-mapk-signalling-pathway
#27
JOURNAL ARTICLE
Jing Tian, Wenjing Li, Lu Zeng, Yang Li, Jiamin Du, Ying Li, Bin Li, Guohai Su
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of total heart failure patients and is characterized by peripheral circulation, cardiac remodelling and comorbidities (such as advanced age, obesity, hypertension and diabetes) with limited treatment options. Chidamide (HBI-8000) is a domestically produced benzamide-based histone deacetylase isoform-selective inhibitor used for the treatment of relapsed refractory peripheral T-cell lymphomas. Based on our in vivo studies, we propose that HBI-8000 exerts its therapeutic effects by inhibiting myocardial fibrosis and myocardial hypertrophy in HFpEF patients...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38509698/the-epidemiological-characteristics-of-sleep-disordered-breathing-in-congestive-heart-failure-a-prospective-single-centre-study-in-southeast-asia
#28
JOURNAL ARTICLE
Albert Iruthiaraj Lourdesamy Anthony, Rosilawati Abdul Rani
BACKGROUND: The presence of sleep-disordered breathing (SDB) in congestive heart failure (CHF) is associated with poor prognosis and is underdiagnosed despite advances in CHF management. The prevalence of SDB in CHF remains understudied in South East Asia. METHODS: A prospective, observational single-centre study was conducted where 116 consecutive patients in a specialised heart failure clinic underwent level 1, attended polysomnography (PSG). RESULTS: The prevalence of SDB was 78% using the apnoea-hypopnea index (AHI), AHI ⩾ 5/h threshold, and 59% with the AHI ⩾ 15/h threshold...
March 20, 2024: Journal of the Royal College of Physicians of Edinburgh
https://read.qxmd.com/read/38509642/cost-effectiveness-of-dapagliflozin-for-patients-with-heart-failure-across-the-spectrum-of-ejection-fraction-a-pooled-analysis-of-dapa-hf-and-deliver-data
#29
JOURNAL ARTICLE
Jason A Davis, David Booth, Phil McEwan, Scott D Solomon, John J V McMurray, Rudolf A de Boer, Josep Comin-Colet, Erasmus Bachus, Jieling Chen
AIM: To assess the cost-effectiveness of dapagliflozin in addition to usual care, compared with usual care alone, in a large population of patients with heart failure (HF), spanning the full range of left ventricular ejection fraction (LVEF). METHODS AND RESULTS: Patient-level data were pooled from HF trials (DAPA-HF, DELIVER) to generate a population including HF with reduced, mildly reduced and preserved LVEF, to increase statistical power and enable exploration of interactions among LVEF, renal function and N-terminal pro-B-type natriuretic peptide levels, as they are relevant determinants of health status in this population...
March 20, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38509461/risk-factors-for-pregnancy-associated-heart-failure-with-preserved-ejection-fraction-and-adverse-pregnancy-outcomes-a-cross-sectional-study
#30
JOURNAL ARTICLE
Seon Ui Lee, Jae Young Park, Subeen Hong, Jeong Ha Wie, Jae Eun Shin, Sae Kyung Choi, Woo Jeng Kim, Yeon Hee Kim, Yun Sung Jo, In Yang Park, Kicheol Kil, Hyun Sun Ko
BACKGROUND: Although pregnancy-associated heart failure with preserved ejection fraction (HFpEF) is increasing and contributing to maternal morbidity, little is known about its impact on pregnancy. We examined the risk factors for and adverse pregnancy outcomes of HFpEF in pregnant women. METHODS: We conducted a cross-sectional analysis of pregnancy-related hospitalizations from 2009 to 2020 using the perinatal database of seven multicenters. Cases of HFpEF were identified using the International Classification of Diseases and echocardiography findings...
March 20, 2024: BMC Pregnancy and Childbirth
https://read.qxmd.com/read/38509041/plethysmography-a-game-changer-for-chronic-venous-insufficiency-diagnosis-treatment-and-follow-up
#31
JOURNAL ARTICLE
Hakan Guven
OBJECTIVE: Chronic Venous Insufficiency (CVI) presents a various clinical symptoms and treatment options. Although it is generally known which treatment option is more appropriate in which situations in CVI, it is even more difficult to find the right option in some uncertain situations. In this study, we aimed to evaluate the potential contribution of Digital Photoplethysmography (D-PPG) in the diagnosis of CVI and especially in the selection of treatment options. PATIENTS AND METHOD: This retrospective study was conducted at Bursa Heart and Arrhythmia Hospital, involving 721 consecutive patients diagnosed with CVI and with Endovenous Laser Ablation (EVLA) indication...
March 20, 2024: Vascular
https://read.qxmd.com/read/38508321/a-nomogram-for-predicting-the-risk-of-heart-failure-with-preserved-ejection-fraction
#32
JOURNAL ARTICLE
Li Hua, Rong Zhang, Ruichang Chen, Wenming Shao
BACKGROUND: This study purposed to design and establish a nomogram to predict the risk of having heart failure with preserved ejection fraction. METHOD: The clinical data of 1031 patients diagnosed with heart failure (HF) in the First Affiliated Hospital of Jinan University from January 2018 to December 2022 were retrospectively analyzed, among which 618 patients were diagnosed with heart failure with preserved ejection fraction (HFpEF). Patients were randomly divided into a training set (70%, n = 722) and a validation set (30%, n = 309)...
March 18, 2024: International Journal of Cardiology
https://read.qxmd.com/read/38507681/cardiac-remodeling-novel-pathophysiological-mechanisms-and-therapeutic-strategies
#33
JOURNAL ARTICLE
Motohiro Nishida, Xinya Mi, Yukina Ishii, Yuri Kato, Akiyuki Nishimura
Morphological and structural remodeling of the heart, including cardiac hypertrophy and fibrosis, has been considered a therapeutic target for heart failure for approximately three decades. Groundbreaking heart failure medications demonstrating reverse remodeling effects have contributed significantly to medical advancements. However, nearly 50% of heart failure patients still exhibit drug resistance, posing a challenge to the healthcare system. Recently, characteristics of heart failure resistant to ARBs and β-blockers have been defined, highlighting preserved systolic function despite impaired diastolic function, leading to the classification of heart failure with preserved ejection fraction (HFpEF)...
March 20, 2024: Journal of Biochemistry
https://read.qxmd.com/read/38507022/new-perspectives-in-the-echocardiographic-hemodynamics-multiparametric-assessment-of-patients-with-heart-failure
#34
REVIEW
Matteo Lisi, Giovanni Andrea Luisi, Maria Concetta Pastore, Giulia Elena Mandoli, Giovanni Benfari, Federica Ilardi, Alessandro Malagoli, Simona Sperlongano, Michael Y Henein, Matteo Cameli, Antonello D'Andrea
International Guidelines consider left ventricular ejection fraction (LVEF) as an important parameter to categorize patients with heart failure (HF) and to define recommended treatments in clinical practice. However, LVEF has some technical and clinical limitations, being derived from geometric assumptions and is unable to evaluate intrinsic myocardial function and LV filling pressure (LVFP). Moreover, it has been shown to fail to predict clinical outcome in patients with end-stage HF. The analysis of LV antegrade flow derived from pulsed-wave Doppler (stroke volume index, stroke distance, cardiac output, and cardiac index) and non-invasive evaluation of LVFP have demonstrated some advantages and prognostic implications in HF patients...
March 20, 2024: Heart Failure Reviews
https://read.qxmd.com/read/38506045/virus-induced-acute-respiratory-distress-syndrome-causes-cardiomyopathy-through-eliciting-inflammatory-responses-in-the-heart
#35
JOURNAL ARTICLE
Jana Grune, Geetika Bajpai, Pervin Tülin Ocak, Eva Kaufmann, Kyle Mentkowksi, Steffen Pabel, Nina Kumowski, Fadi E Pulous, Kim A Tran, David Rohde, Shuang Zhang, Yoshiko Iwamoto, Gregory R Wojtkiewicz, Claudio Vinegoni, Ursula Green, Filip K Swirski, James R Stone, Jochen K Lennerz, Maziar Divangahi, Maarten Hulsmans, Matthias Nahrendorf
BACKGROUND: Viral infections can cause acute respiratory distress syndrome (ARDS), systemic inflammation, and secondary cardiovascular complications. Lung macrophage subsets change during ARDS, but the role of heart macrophages in cardiac injury during viral ARDS remains unknown. Here we investigate how immune signals typical for viral ARDS affect cardiac macrophage subsets, cardiovascular health, and systemic inflammation. METHODS: We assessed cardiac macrophage subsets using immunofluorescence histology of autopsy specimens from 21 patients with COVID-19 with SARS-CoV-2-associated ARDS and 33 patients who died from other causes...
March 20, 2024: Circulation
https://read.qxmd.com/read/38504576/utility-of-a-fusion-protein-t-cell-co-stimulation-blocker-belatacept-in-heart-transplant-recipients-real-world-experience-from-a-high-volume-center
#36
JOURNAL ARTICLE
Daniel Oren, Matan Uriel, Cathrine M Moeller, Andrea Fernandez Valledor, Ersilia M DeFilippis, Dor Lotan, Paolo C Colombo, Melana Yuzefpolskaya, Veli K Topkara, Kevin J Clerkin, Jayant K Raikhelkar, Justin A Fried, David Kyung Taek Oh, David Bae, Eddie Lin, Kleanthis Theodoropoulos, Yoshifumi Naka, Koji Takeda, Jason Choe, Douglas L Jennings, David Majure, Farhana Latif, Gabriel Sayer, Nir Uriel
BACKGROUND: Belatacept (BTC), a fusion protein, selectively inhibits T-cell co-stimulation by binding to the CD80 and CD86 receptors on antigen-presenting cells (APCs) and has been used as immunosuppression in adult renal transplant recipients. However, data regarding its use in heart transplant (HT) recipients are limited. This retrospective cohort study aimed to delineate BTC's application in HT, focusing on efficacy, safety, and associated complications at a high-volume HT center. METHODS: A retrospective cohort study was conducted of patients who underwent HT between January 2017 and December 2021 and subsequently received BTC as part of their immunosuppressive regimen...
March 2024: Clinical Transplantation
https://read.qxmd.com/read/38503670/a-non-invasive-nomogram-for-predicting-heart-failure-with-preserved-ejection-fraction-in-taiwanese-outpatients-with-unexplained-dyspnea-and-fatigue
#37
JOURNAL ARTICLE
Yi-Wei Chung, Jen-Fang Cheng, Yen-Liang Lin, Hung-Jui Chuang, Chia-Chuan Chuang, Cheng-Wei Chen, Wei-Ming Huang, Cho-Kai Wu, Lian-Yu Lin
BACKGROUND: While Reddy proposed the H2FPEF diagnostic algorithm to aid in diagnosing heart failure with preserved ejection fraction (HFpEF), certain parameters like age and obesity are not suitable for Asian population, especially given the increasing incidence of HFpEF in younger individuals. Therefore, this study aimed to develop an easy-to-use nomogram with non-invasive indices that can be used in outpatient clinics in Taiwan to quickly estimate the probability of HFpEF and help decide whether further invasive cardiopulmonary exercise test (CPET) is needed...
March 18, 2024: Journal of the Formosan Medical Association
https://read.qxmd.com/read/38501484/renal-perturbations-with-sodium-glucose-cotransporter-2-inhibitor-in-heart-failure-with-preserved-ejection-fraction
#38
EDITORIAL
Simon Vanhentenrijk, W H Wilson Tang
No abstract text is available yet for this article.
March 19, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38500750/cardiometabolic-biomarker-patterns-associated-with-cardiac-mri-defined-fibrosis-and-microvascular-dysfunction-in-patients-with-heart-failure-with-preserved-ejection-fraction
#39
JOURNAL ARTICLE
Connor Siggins, Jonathan A Pan, Adrián I Löffler, Yang Yang, Peter W Shaw, Pelbreton C Balfour, Frederick H Epstein, Li-Ming Gan, Christopher M Kramer, Ellen C Keeley, Michael Salerno
INTRODUCTION: Heart failure with preserved ejection fraction (HFpEF) is a complex disease process influenced by metabolic disorders, systemic inflammation, myocardial fibrosis, and microvascular dysfunction. The goal of our study is to identify potential relationships between plasma biomarkers and cardiac magnetic resonance (CMR) imaging markers in patients with HFpEF. METHODS: Nineteen subjects with HFpEF and 15 age-matched healthy controls were enrolled and underwent multiparametric CMR and plasma biomarker analysis using the Olink® Cardiometabolic Panel (Olink Proteomics, Uppsala, Sweden)...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38500304/assessing-the-impact-of-haemodynamic-monitoring-with-cardiomems-on-heart-failure-patients-a-cost-benefit-analysis
#40
JOURNAL ARTICLE
Pau Codina, José Ángel Vicente Gómez, Guillem Hernández Guillamet, Laura Ricou Ríos, Andrea Carrete, Victoria Vilalta, Oriol Estrada, Jordi Ara, Josep Lupón, Antoni Bayés-Genís, Francesc López Seguí
AIMS: The objective of this study was to perform a cost-benefit analysis of the CardioMEMS HF System (Abbott Laboratories, Abbott Park, IL, USA) in a heart failure (HF) clinic in Spain by evaluating the real-time remote monitoring of pulmonary artery pressures, which has been shown to reduce HF-related hospitalizations and improve the quality of life for selected HF patients. Particularly, the study aimed to determine the value of CardioMEMS in Southern Europe, where healthcare costs are significantly lower and its effectiveness remains uncertain...
March 18, 2024: ESC Heart Failure
keyword
keyword
52792
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.